Manufactures preventive nutrition and wellness products at a facility in Udham Singh Nagar (Uttarakhand) and operates from Hyderabad (Telangana), selling them through Wellness Marts, online platforms and export markets. The company is expanding its wellness portfolio into hydration and sports nutrition products. It also runs a subsidiary called Beyoungstore Private Limited, whose results are folded into the consolidated accounts. In FY26, consolidated revenue was Rs 81.9048 crore and net profit Rs 2.4876 crore, with materials forming the largest cost at 64.3% of revenue. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Preventive nutrition and wellness products, Hydration and sports nutrition (new pipeline), Beyoungstore (subsidiary). Small-cap branded preventive nutrition and wellness manufacturer with retail (Wellness Marts), online and export distribution.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 33 | 45 | 60 | 75 | 82 |
| EBITDA (ex other income) | — | — | 4 | 3 | 5 |
| margin % | — | — | 6.3 | 4.2 | 6.2 |
| Owners' profit | — | — | 1 | 1 | 0 |
| EPS, as reported (₹) | 0.21 | 0.22 | 0.80 | 0.54 | 1.01 |
| ROE % · ROCE % | — · 0.9 | — · 0.7 | 1.5 · 2.3 | 1.1 · 1.6 | 2.3 · 3.2 |
| Debt / equity (x) | — | — | 0.02 | 0.01 | 0.04 |
| Cash from operations | (1) | (7) | (13) | (6) | (4) |
| Capex | — | — | (0) | 0 | (3) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 19 | 20 | 21 | 22 | 21 | 17 | 21 | 22 |
| Profit before tax | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Net profit | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| EPS (₹) | 0.26 | 0.07 | 0.05 | 0.10 | 0.37 | 0.41 | 0.14 | 0.12 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DR. LAL PATH LABS LTD. | 31,794 | 45.7 | 12.51 | 37.0 | 20.1 | 24.8 | 11.8 | 35.0 |
| VIJAYA DIAGNOSTIC CEN LTD | 15,456 | 82.4 | 16.15 | 43.1 | 18.1 | 16.8 | — | 46.4 |
| METROPOLIS HEALTHCARE LTD | 12,088 | 25.0 | 7.93 | 28.9 | 12.5 | 14.4 | 10.5 | 25.8 |
| THYROCARE TECH LTD | 8,797 | 32.3 | 15.01 | 32.1 | 27.8 | 33.2 | 10.9 | 33.9 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 10 Sept 2026 · Deccan Health Care Annual Report FY25-26: Revenue up 18.7%, PAT up 91% | general | high | — | — |
| 8 Sept 2026 · Newspaper clippings for 30th AGM notice and e-voting filed with BSE | compliance | minimal | — | — |
| 7 Sept 2026 · Book Closure & E-Voting Intimation for 30th AGM on 30 Sep 2026 | board shareholder meetings | low | — | — |
| 7 Sept 2026 · FY25-26 Annual Report: Revenue up 18.7 percent, PAT nearly doubles | results | high | — | — |
| 7 Sept 2026 · Notice of 30th AGM on 30 September 2026 via video conferencing | board shareholder meetings | low | — | — |
| 17 Aug 2026 · Newspaper Publication of Q1 FY27 Financial Results Filed with BSE | compliance | minimal | — | — |
| 14 Aug 2026 · Deccan Health Care Q1FY27 Results: PAT Rs 24.63 lakh, Revenue Rs 21.86 cr | results | high | — | — |
| 6 Aug 2026 · Board Meeting on 14 Aug 2026 to approve Q1 FY26-27 Financial Results | results | low | — | — |
| 27 Jul 2026 · EGM Results: 3 Independent Director Appointments Approved | compliance | minimal | — | — |
| 24 Jul 2026 · Regularization of 3 Independent Directors Approved at EGM | management changes | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| NEPHROCARE HEALTH SERV L |
| 7,678 |
| 79.3 |
| 6.88 |
| 30.4 |
| 6.9 |
| 8.6 |
| — |
| 25.3 |
| KRSNAA DIAGNOSTICS LTD | 1,794 | 18.4 | 1.83 | 9.0 | 10.3 | 8.4 | — | 27.7 |
| SURAKSHA DIAGNOSTIC LTD | 1,693 | 47.2 | 6.95 | 17.2 | 12.9 | 11.5 | — | 36.0 |
| 3B BLACKBIO DX LTD. | 1,217 | 20.3 | 3.67 | 14.3 | 18.1 | 22.5 | (8.9) | 52.6 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 12.0 | 23.2 | 7 of 29 | 79% |
| P/B | 0.3 | 2.3 | 2 of 24 | 96% |
| ROCE | 2.8 | 6.1 | 19 of 29 | 36% |
| ROE | 2.3 | 7.3 | 18 of 26 | 32% |
| Debt / Equity | 0.0 | 0.0 | 14 of 26 | 48% |
| EBITDA margin | 4.2 | 25.6 | 20 of 24 | 17% |
| Revenue growth | (0.3) | 20.8 | 22 of 25 | 13% |
| Profit growth | 22.8 | 22.0 | 12 of 25 | 54% |
| Market cap | 31 | 38 | 17 of 30 | 45% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
